SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001387131-22-005630
Filing Date
2022-05-02
Accepted
2022-05-02 17:05:00
Documents
5
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT TO FORM 10-K admp-10ka_123121.htm 10-K/A 692411
2 CERTIFICATION BY CEO PURSUANT TO SECTION 302 ex31-1.htm EX-31.1 16796
3 CERTIFICATION BY CFO PURSUANT TO SECTION 302 ex31-2.htm EX-31.2 17078
4 CERTIFICATION BY CEO PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 ex32-1.htm EX-32.1 8014
5 CERTIFICATION BY CFO PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 ex32-2.htm EX-32.2 8023
  Complete submission text file 0001387131-22-005630.txt   743458
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36242 | Film No.: 22883039
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences